Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects

ConditionHealthy Subjects

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age19-54

SponsorYuhan Corporation

About this trial

An open-label, randomized, fasting, single-dose, oral administration, 2-sequence, 4-period, replicate crossover study to evaluate bioequivalence between YHP2508C and YHR2603 in healthy subjects

Eligibility criteria

Qualifiers

BMI 18-30 kg/m2

Those without clinically significant congenital or chronic diseases

Disqualifiers

Those who have participated in a bioequivalence study or other clinical trials and have been administered investigational products within 6 months prior to the first administration.

Those who are judged ineligible to participate in the trial by the principal investigator.

Female volunteers who are pregnant, suspected to be pregnant or breastfeeding.

Trial design

Treatments tested in this trial

YHP2508C
YHR2603

Treatment groups

44 Participants

are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Yuhan Corporation

Lead sponsor

Source ClinicalTrials.gov